CODEN [USA]: IAJPBB ISSN : 2349-7750

INDO AMERICAN JOURNAL OF
PHARMACEUTICAL SCIENCES

SJIF Impact Factor: 7.187

https://doi.org/10.5281/zenodo.16788444

Available online at: http://www.iajps.com Review Article

A REVIEW ON INFLAMMASOMES AND CARDIOVASCULAR DISEASE: THE NLRP3 AXIS AS A THERAPEUTIC FRONTIER

Rohith Yadav [1], Shubamalya LG [2]

[1] Pharm.D, Physician Assistance, Continental Hospital, Hyderabad

[2] Pharm.D, Rao's college of pharmacy, Nellore

Abstract:

Cardiovascular diseases (CVDs) are the leading worldwide cause of morbidity and mortality, inflammation being one of the main factors in their pathology. Inflammasomes, NLRP3 in particular, were identified as central mediators of sterile inflammation processes. NLRP3 inflammasomes are cytosolic multiprotein complexes that control caspase-1 activation and subsequent maturation of pro-inflammatory cytokines IL-1β and IL-18. With growing evidence, NLRP3 inflammasome has been implicated in CVDs like atherosclerosis, myocardial infarction, heart failure, and hypertension. Their activation causes endothelial dysfunction, vascular inflammation, destabilization of plaques, and adverse cardiac remodeling. Targeting the NLRP3 axis therapeutically has been promising in both preclinical and clinical studies, thus presenting NLRP3 as a potential new target in cardiovascular therapy. This study reviews the mechanistic insights of NLRP3 inflammasome activation, its involvement in cardiovascular diseases, current therapeutic strategies, and hurdles in clinical translation. Exploration of this inflammasome axis brings new avenues for precision medicine and targeted interventions for cardiovascular health.

Keywords: *NLRP3, inflammasome, cardiovascular disease, inflammation, IL-1β, atherosclerosis, myocardial infarction, heart failure.*

Corresponding author:

Rohith Yadav,

Pharm.D, Physician Assistance,

Continental Hospital, Hyderabad

QR CODE

Please cite this article in press ***Rohith Yadav*** *et al.,* ***A Review On Inflammasomes And Cardiovascular Disease: The Nlrp3 Axis As A Therapeutic Frontier****., Indo Am. J. P. Sci, 2025; 12(08).*

INTRODUCTION:

World Health Organization (WHO) estimates that approximately 17.9 million deaths occur each year due to cardiovascular diseases (CVDs), thus accounting for almost 32% of all deaths across the globe. The wide spectrum of disorders comprises diseases of the heart and blood vessels--such as coronary artery disease, heart failure, stroke, and peripheral arterial disease. The burden is made intolerable by being confronted chiefly in low- and middle-income countries, which account for 75% of cardiovascular deaths because of inadequate access to preventive and therapeutic health services. The increasing prevalence of risk factors such as obesity, diabetes, hypertension, smoking, sedentary lifestyles, and the aging population further facilitated the worldwide impact of cardiovascular diseases. Besides mortality, CVDs also stand for immense disability, diminution of life quality, and mounting healthcare costs; thus, they are worthy of public health challenges calling for immediate attention and innovative treatment approaches.[1]

Although traditional risk factors, such as dyslipidemia, hypertension, and diabetes, are well-documented, increasing evidence underscores the pivotal role of inflammation in the inception, propagation, and consequences of cardiovascular disease (CVD). Chronic low-level inflammation fosters endothelial dysfunction, stimulates atherogenesis, and destabilizes atherosclerotic plaques, thereby raising the risk of events such as myocardial infarction or stroke. Sterile inflammation mechanisms, especially innate immunity, have arisen as key core mediators in cardiovascular pathology. Inflammasomes, particularly the NOD-, LRR-, and pyrin domain-containing 3 (NLRP3) inflammasome, serve as intracellular sensors that, when triggered by salient cellular stress and danger signals, initiate the inflammatory cascade. These inflammasomes foster the generation of potent proinflammatory cytokines, IL-1β and IL-18, which have been implicated in plaque formation, myocardial remodeling, and vascular injury. Recognition and modulation of these inflammatory pathways signify a shift in the paradigm of cardiovascular disease prevention and treatment.[2]

An inflammasome represents an intracellular multimolecular protein complex that essentially helps the innate immune system by sensing the presence of pathogenic microorganisms or sterile signals of stress. First described in 2002, inflammasomes serve as a recognition platform, identifying DAMPs and PAMPs via special receptors such as NLRs or ALRs. Upon activation, the inflammasomes induce the oligomerization of the adaptor protein ASC and activate caspase-1, which then performs cleavage of pro-IL-1β and pro-IL-18 into their mature forms, inducing an inflammatory response and, in some cases, pyroptosis- an inflammatory- programmed cell-death. In the initial days, they were characterized as a cytoprotective mechanism against infectious agents; obviously, inflammasomes activation, particularly the NLRP3 subtype, is also triggered during sterile inflammatory states like metabolic disease, neurodegeneration, and cardiovascular disease.[3]

Among the different kinds of inflammasomes, the NLRP3 inflammasome has attracted enormous attention because it uniquely reacts to a diverse array of stimuli, such as cholesterol crystals, ROS, ATP, and oxLDL-herein meaning symbols relevant to cardiovascular pathology. Activation of NLRP3 has been found allied with the developmental and progression phases of the atherosclerosis, myocardial infarction, heart failure, and hypertension. Downstream effectors of the inflammasome, IL-1β and IL-18, center on vascular inflammation, endothelial dysfunction, cardiac remodeling, and plaque instability. Pharmacologic inhibition of NLRP3 or its cytokines has shown encouraging results in preclinical studies and few clinical trials. The landmark CANTOS trial targeting IL-1β proved conceptually that reduction of cardiovascular events is possible with modulation of inflammation. Hence, NLRP3 inflammasome emphasis holds interest, not only as a novel mechanism implicated in the pathogenesis of CVD but also as a promising therapeutic method that would work alongside traditional risk factor modification.[4]

BIOLOGY OF INFLAMMASOMES

The innate immune system works as a first-line barrier, keeping pathogens and tissue injury at bay. It uses PRRs (pattern recognition receptors) to bind conserved microbial motifs called pathogen-associated molecular patterns (PAMPs) and host-derived danger signals called danger-associated molecular patterns (DAMPs). These PRRs include TLRs (Toll-like receptors), CLRs (C-type lectin receptors), RLRs (RIG-I-like receptors) and NLRs (NOD-like receptors). Members of the NLR family that are capable of forming inflammasome complexes upon activation include NLRP1, NLRP3, and NLRC4. These receptors perceive numerous stimuli such as microbial products, environmental irritants, and metabolic stressors and respond downstream by triggering inflammatory mechanisms essential for innate immunity and tissue repair.[5]

Structure and Components of Inflammasomes

Inflammasomes are multiprotein assembly complexes that assemble in the cytoplasm of innate

immune cells whenever the latter is subjected to adverse stimuli. Inflammasomes carry almost all inflammatory activities by maturing interleukin-1β (IL-1β) and interleukin-18 (IL-18) and pyroptotic cell death. Canonically, an inflammasome comprises three main components:

1. Sensor Protein

The sensor is the pattern recognition receptor that senses the danger signals, essentially. These sensors are commonly members of the NOD-like receptor family (e.g. NLRP3, NLRP1, NLRC4, etc.) or AIM2-like receptors (ALRs) like AIM2, for example. These proteins have distinct domains that dedicatedly allow for signal sensing and oligomerization:

- Pyrin domain (PYD): Involved in protein–protein interactions, specifically with ASC.
- Nucleotide-binding domain (NBD or NACHT domain): Important for oligomerization.
- Leucine-rich repeat (LRR) domain: involved in ligand sensing and autoregulation.[6]

2. Adaptor Protein (ASC)

ASC is a bridge molecule that links the sensor to the effector caspase. ASC contains:

- A pyrin domain (PYD) at the N-terminus that interacts with the PYD of the sensor.
- A caspase activation and recruitment domain (CARD) at the C-terminus that binds to pro-caspase-1.

Following sensor activation, ASC molecules oligomerize into a speck-like structure that acts as a central signaling hub for the recruitment and activation of caspase-1.[7]

3. Effector Enzyme (Caspase-1)

Inactive Caspase-1 in its precursor form is called pro-caspase-1. After recruitment to the inflammasome by CARD-CARD interactions with ASC, pro-caspase-1 undergoes self-cleavage to become active. Active caspase-1 exert two primary functions:

- To cleave pro-IL-1β and pro-IL-18 into their mature and secreted forms, which are powerful mediators of inflammation.
- To cleave GSDMD or gasdermin D for pore formation in the cell membrane initiating pyroptosis-an inflammatory programmed cell death.[8]

MECHANISM OF ACTIVATION

Priming and Activation Signals

This process is considered accomplished when a two-step activation of the inflammasome, particularly the NLRP3 inflammasome, occurs: priming and activation. Priming is the first step in this process and normally involves exogenous signals such as microbial molecules (PAMPs) or endogenous signals of danger or stress (DAMPs) detected by receptors such as TLRs or cytokines. This in turn activates the NF-κB signaling pathway that promotes upregulation of the transcripts of many important inflammasome components like NLRP3, pro-IL-1β, pro-IL-18, and pro-caspase-1. These proteins are necessary for inflammasome formation but remain inactive during this stage. Activation, the second step, occurs when a cell perceives signals of stress, such as potassium efflux, mitochondrial dysfunction, lysosomal damage, or reactive oxygen species (ROS), causing a conformational change to NLRP3 that permits its interaction with ASC and pro-caspase-1 into the inflammasome complex. Once the inflammasome complex is formed, caspase-1 activity is triggered, leading to the processing of mature IL-1β and IL-18, and causing pyroptosis, which is an inflammatory form of cell death.[9]

Canonical Pathway

The canonical pathway stands as the classic route for inflammasome activation and leads to direct activation of caspase-1 by the assembly of the inflammasome complex. Upon receiving provocation and activation signals, NLRP3 oligomerizes and recruits an adaptor protein, ASC, which in turn binds the pro-caspase-1. This juxtaposition provides the proximity needed for caspase-1 to be autocatalytically cleaved into the active enzyme. Activation of the caspase-1 enzyme leads to the processing of pro-IL-1β and pro-IL-18 into their mature cytokines, which are secreted from the cell in order to instigate a strong inflammatory response. The caspase-1 enzyme also accepts gasdermin D as a substrate, cleaving it and causing it to assemble in the cell membrane, thereby forming pores and inducing pyroptosis in target cells. This pathway is considered to be especially relevant in sterile inflammatory diseases where either atherogenesis or myocardial infarction or heart failure occurs, thereby making inflammation an autonomous endogenous stress signal.[10]

Non-Canonical Pathway

The atypical inflammasome activation operates in a caspase-1-independent fashion, with caspase-4/5 in humans and caspase-11 in mice. Intracellular LPS of Gram-negative bacteria nature triggers this pathway. Upon cytoplasmic entry of LPS, it binds directly to and activates these caspases of the non-canonical variety. In contrast to the canonical pathway, caspase-4/5/11 do not directly cleave IL-1β or IL-18; instead, they cleave gasdermin D, resulting in pyroptosis. Ion fluxes and membrane damages, specifically potassium efflux, may then act as a second signal that triggers the canonical NLRP3 inflammasome and incites inflammation. The multiplicity of the pathway is most commonly

seen with bacterial infections but may come in handy in exacerbating inflammation in cardiovascular disease when infection and chronic inflammation feed each other.[11]

TYPES OF INFLAMMASOMES AND THEIR LIGANDS

The different kinds of inflammasomes characterized thus far differ in terms of their sensor proteins. These comprise:

- **NLRP1 inflammasome**: activated in response to Bacillus anthracis lethal toxin and other stimuli.
- **NLRP3 inflammasome**: these react to an extremely diverse set of PAMPs and DAMPs, including uric acid crystals, cholesterol crystals, ATP, and ROS.
- **NLRC4 inflammasome**: senses intracellular bacterial components such as flagellin.
- **AIM2 inflammasome**: recognizes cytosolic double-stranded DNA.
- **Pyrin inflammasome**: activated by bacterial toxins that inactivate Rho GTPases..

Among them, NLRP3 is said to have the unusual capability to respond to a versatile array of sterile stimuli and hence is of particular interest to non-infectious chronic inflammatory diseases such as atherosclerosis and heart failure.[12]

NLRP3 INFLAMMASOME: A CENTRAL PLAYER

The NLRP3 inflammasome has been established as the principal mediator of inflammatory pathways in CVDs. As the primary machinery of innate immunity, NLRP3 senses a battery of danger signals-cholesterol crystals, reactive oxygen species (ROS), mitochondrial dysfunction, extracellular ATP-many of which are prominent in cardiovascular traumas such as atherosclerosis, myocardial infarction, and heart failure. On activation, NLRP3 forms a multiprotein complex that activates caspase-1; in turn, caspase-1 causes the release of numerous pro-inflammatory cytokines, including interleukin-1β (IL-1β) and interleukin-18 (IL-18), while at the same time inducing pyroptosis, another inflammatory cell death pathway. These events not only exacerbate local tissue damage but also help promote systemic inflammation, endothelial dysfunction, and plaque instability. Since NLRP3 is central to linking metabolic stress and immune activation, this endows the inflammasome with significance as a master regulator of cardiovascular inflammation and with high potential as a target for therapeutic intervention.[13]

Structure and Function of NLRP3

NLRP3, the protein, stands as a cytosolic pattern-recognition receptor and is one member amongst the family of NOD-like receptors. Structurally, three important domains give NLRP3 its structure: an N-terminal Pyrin domain (PYD), a center NACHT domain responsible for ATP-mediated oligomerization, and an LRR (leucine-rich repeat) domain at the C-terminal that detects stress signals and performs autoregulation. Changes take place in the conformation of the protein after exposure to DAMPs or PAMPs that permit it to undergo oligomerization through its NACHT domain. The PYD domain interacts with the adaptor protein ASC (apoptosis-associated speck-like protein containing a CARD), which consequently recruits pro-caspase-1 by CARD-CARD interaction. This multi-protein complex is converted into the active NLRP3 inflammasome, which induces the autocatalytic activation of caspase-1. Activated caspase-1 cleaves pro-IL-1β and pro-IL-18 into their mature forms and induces pyroptosis, an inflammatory form of programmed cell death.[14]

NLRP3 acts as a sensor on top of molecular stimuli and in turn serves to amplify innate immune responses during cellular stress, infection, or tissue injury, thus being an important player in sterile inflammation occurring in cardiovascular diseases.

Activation Mechanisms of NLRP3

Activation of the NLRP3 inflammasome is a strictly controlled, two-step process comprising priming and activation signals. The priming step is induced by signals such as cytokines (e.g., TNF-α, IL-1β) or microbial components (such as lipopolysaccharides), giving an activating stimulus to the NF-κB pathway. In turn, NLRP3, pro-IL-1β, and pro-IL-18 genes are all upregulated and transcribed, forming a cellular environment suitable for inflammasome assembly. The activation step is initiated by several cellular stressors inducing a conformational change in the NLRP3 protein. These include extracellular ATP, ROS, cholesterol crystals, oxidized LDL, mitochondrial dysfunction, and potassium efflux. This change enables oligomerization of NLRP3 and its recruitment of the adaptor protein ASC, which then recruits pro-caspase-1 and induces its activation. Caspase-1 activation cleaves the pro-forms of IL-1β and IL-18 into their mature forms, and caspase-1 also induces pyroptosis, an inflammatory programmed cell death. Additionally, the canonical and non-canonical pathways have been described, with the canonical pathway involving the direct cleavage of NLRP3 by caspase-1, whereas the non-canonical pathway involves intracellular LPS activation of caspase-4/5 (in humans), which, downstream, leads to the activation of NLRP3. These activation mechanisms ensure that the NLRP3 inflammasome will only be

turned on in the presence of genuine stress or danger, but a chronic or inappropriate activation is closely associated with cardiovascular pathologies.[15,16]



Figure 1 : Activation Mechanisms of NLRP3

Regulation of NLRP3 Activity

The activity of the NLRP3 inflammasome is regulated at multiple levels to avoid pathological inflammation and tissue damage. The transcriptional regulation is considered another important control instance, wherein the pathway activations, such as NF-κB, induce expressions of NLRP3 and pro-inflammatory cytokines, including pro-IL-1β and pro-IL-18. Beyond transcription, the post-translational modifications (PTMs) such as ubiquitination, phosphorylation, and sumoylation may affect either the activation or suppression of NLRP3 functions. For example, ubiquitination may render NLRP3 inactive, whereupon removal of ubiquitin by deubiquitinases (e.g., BRCC3) triggers inflammasome activation. Phosphorylation of certain domains of NLRP3 can promote its assembly or prevent its activation, depending on the domain and circumstance.

Moreover, it is autophagy that is involved in the regulation by destroying damaged mitochondria and restricting mitochondrial ROS, known NLRP3 activators. Besides, proteins such as NLRP10 and CARD-only proteins (COPs) or PYD-only proteins (POPs) constitute endogenous inhibitors that block NLRP3-ASC interactions or prevent oligomerization. These numerous layers of regulation act to ensure that NLRP3 is activated only in response to appropriate danger signals and thus preserve immune homeostasis, being of major importance toward averting chronic cardiovascular inflammation.[17]

NLRP3 INFLAMMASOME: A KEY MEDIATOR IN CARDIOVASCULAR PATHOPHYSIOLOGY

1. Triggering Factors in Cardiovascular Tissues

Various cardiovascular stress signals activate the NLRP3 inflammasome: cholesterol crystal, ROS, oxidative LDL, ATP, and calcium overload. These danger signals occur within damaged heart tissue and atherosclerotic plaques, leading to an immune

response that triggers chronic inflammation and tissue remodeling.[18]

2. Priming Phase via NF-κB Activation

The first step of NLRP3 activation, called priming, occurs by stimuli such as TNF-α or an oxidized lipid signal. The activation of the NF-κB signaling pathway in cardiac macrophages, endothelial cells, and cardiomyocytes causes the cells to upregulate transcription of NLRP3, pro-IL-1β, and pro-IL-18, thus preparing them for the assembly of the inflammasome

3. Assembly and Activation of NLRP3 Complex

NLRP3 faces structural alterations and oligomerization triggered by secondary stimuli such as ATP and ROS. It then enlists ASC (apoptosis-associated speck-like protein containing a CARD), which binds procaspase-1 to form the active NLRP3 inflammasome with enzymatic activity.[19]

4. Caspase-1 Activation and Cytokine Release

The activated inflammasome converts the inactive procaspase-1 to active caspase-1, thus dispersing the pro-inflammatory cytokines of pro-IL-1β and pro-IL-18 into mature molecules. These cytokines are launched into the extracellular space to intervene actively in inflammation by directly acting on vascular cells, recruiting immune cells, and promoting endothelial dysfunction in cardiovascular tissues.

5. Induction of Pyroptosis and Amplified Inflammation

In addition to these events, caspase-1 cleaves gasdermin D, leading to pore formation in the cell membrane and pyroptotic cell death-a highly inflammatory cell death. The discharge of intracellular content, which includes DAMPs, further triggers NLRP3 and intensify local inflammation towards tissue damage and plaque instability.[20]

6. Contribution to Cardiovascular Disease Progression

IL-1β and IL-18 from pyroptotic and activated cells promote the expression of adhesion molecules and chemokines from endothelial and smooth muscle cells to cause monocyte infiltration, plaque growth, fibrosis, and maladaptive cardiac remodeling-all mechanisms of disease progression in atherosclerosis, myocardial infarction, and heart failure.

7. Crosstalk with Other Inflammatory Pathways

There is a close association between NLRP3 activation and other pathways such as ROS generation, mitochondrial dysfunction, and Toll-like receptor signaling. IL-1β may further activate NF-κB, thus creating a positive feedback loop. This entire network maintains a state of chronic inflammation in which NLRP3 stands out as a central node of cardiovascular immune signaling.[21]

ROLE OF NLRP3 INFLAMMASOME IN SPECIFIC CARDIOVASCULAR DISEASES

1. Atherosclerosis

Cholesterol crystals and oxidized LDL activate the NLRP3 inflammasome within vascular macrophages, which then induces the release of IL-1β and IL-18, resulting in chronic arterial inflammation, endothelial dysfunction, and plaque formation. Hence, NLRP3-mediated signaling causes plaque instability and, therefore, acts as a critical player in atherogenesis and its progression; targeting it could halt disease progression.[22]

2. Myocardial Infarction (MI)

Ischemic injury, during MI and reperfusion, induces mitochondrial damage and DAMPs, activating NLRP3. This cascade promotes proinflammatory cytokines, aggravating with the death of cardiomyocytes; by expansion of infarct size, the further dimensions of healing get delayed. Therefore, the inhibition of the inflammasome NLRP3 makes the inflammation go down and protects the heart from damage so that remodeling after the infarction and outcome for the patient are improved.[23]

3. Heart Failure (HF)

NLRP3 in its elevated expression is, upon being responded to by hydroxyl free radicals from sources such as ROS, angiotensin II, or the effect of mitochondrial dissidence, initiating cardial fibrogenesis through IL-1β, hypertrophy, and contractile modulations in the myocardium. This system of low-grade chronic inflammation further proceeds with ventricular remodeling, extending its effects into both HFrEF and HFpEF. Hence, with a view towards mitigating the progression of heart failure, NLRP3 inhibition presents itself as a potential therapeutic target.[24]

4. Hypertension

NLRP3 is activated in hypertensive conditions orchestrated by vascular stress and oxidative damage occurring whatsoever in endothelial cells and vascular smooth muscle cells. This instigates a pro-inflammatory state through IL-1β release, vascular remodeling, and endothelial dysfunction. It is conceivable for NLRP3 to interact with renin-angiotensin systems in keeping sustained high blood pressures. Interventions against NLRP3 might restore vascular wellbeing.[25]

5. Atrial Fibrillation (AF)

NLRP3 inflammasome gets synergistically activated by structural remodeling and oxidative stress in atrial tissue. IL-1β promotes fibrosis and conduction abnormalities that foster atrial arrhythmogenesis. The NLRP3 signaling-induced recruitment of inflammatory cells is revealed. Hence, suppressing NLRP3 may reduce recurrence

and worsen progression of AF, especially once it has been ablated or undergone surgery.[26]

6. Stroke (Ischemic)

The NLRP3 gets activated during ischemic stroke by DAMPs and ROS induced by hypoxic conditions acting on brain and vascular cells and increases neuroinflammation, blood-brain barrier disruption, and infarct expansion. IL-1β and IL-18 worsen neuronal injury. Inhibiting NLRP3 might be neuroprotective towards inflammation and improve neurologic recovery post-stroke.[27]

7. Diabetic Cardiomyopathy

High glucose and lipids induce NLRP3 activation in cardiomyocytes in diabetes. Chronic inflammation due to IL-1β encourages myocardial fibrosis, cardiomyocyte hypertrophy, and mitochondrial damage, all of which cause impairment in relaxation and contraction. NLRP3 therefore participates in diabetic cardiac dysfunction and holds promise therapeutically to reverse and improve the outcomes of diabetic heart disease.[28]

THERAPEUTIC TARGETING OF THE NLRP3 INFLAMMASOME

The NLRP3 inflammasome is a principal actor in artery inflammation in CVDs, thus making it an attractive therapeutic target. Multiple pharmacological and biological agents have been developed or repurposed to modulate NLRP3 or its downstream effects, ranging from small molecule drugs to monoclonal antibodies.

1. Direct NLRP3 Inhibitors

The most promising agent would certainly be MCC950 (CRID3), a small-molecule inhibitor that selectively blocks the activation of NLRP3 without affecting other inflammasomes. Preclinical evidence suggests that MCC950 greatly inhibits IL-1β production and inflammation in atherosclerosis, myocardial infarction, and heart failure models. Clinical development, however, was made impossible through concerns about hepatotoxicity. Still, its high selectivity has set the standard for new NLRP3-targeting drugs for example OLT1177 (dapansutrile), which is currently being tested in trials for inflammatory diseases, including CVDs.[29]

2. Downstream Cytokine Blockade: IL-1β and IL-18 Inhibitors

Another approach is to target cytokines down the NLRP3 activation cascade, especially IL-1β. Canakinumab, the monoclonal antibody against IL-1β in the CANTOS trial, significantly reduced recurrent cardiovascular events independently of lipid lowering. Anakinra, an IL-1 receptor antagonist, has also shown some benefits in curtailing systemic inflammation and improving heart-failure symptoms. IL-18, being another inflammasome-related cytokine, still awaits the developing stages of therapy that target it directly.[30]

3. Indirect Inhibitors and Repurposed Drugs

Several existing drugs exert indirect inhibitory effects on the NLRP3 inflammasome:

- Colchicine is a microtubule inhibitor used for gout treatment, and it inhibits the activation of NLRP3. It has also been shown to be promising against cardiovascular events in COLCOT and LoDoCo2 trials.
- Statins being lipid-lowering agents, decrease inflammasome activation by enhancing endothelial function and decreasing oxidative stress.
- SGLT2 inhibitors are for treatment of heart failure and diabetes, and observed to decrease systemic inflammation, possibly via NLRP3 inhibition.[31]

4. Targeting Upstream Activators (ROS, Mitochondrial Dysfunction)

Oxidative stress and mitochondrial dysfunction in the activation of NLRP3 are targeted by various agents. Antioxidants like N-acetylcysteine and mitochondria-targeting chemicals such as MitoQ can inhibit NLRP3 activation indirectly. Inhibitors of potassium efflux, mitochondrial ROS, and lysosomal rupture are under study for controlling upstream activation of the inflammasome.[32]

5. Emerging Therapies and RNA-Based Approaches

Innovative siRNA and antisense oligonucleotide (ASO) therapies are being pushed into development for silencing expression of the NLRP3 gene. These gene-silencing methods tend to be highly specific and hence produce less off-target effects. Using nanoparticles for delivery of NLRP3 inhibitors to inflamed cardiovascular tissues is also being studied for improved bioavailability and specific delivery.[33]

CHALLENGES AND FUTURE DIRECTIONS

1. Specificity and Off-Target Effects

NLRP3 inhibitors may have off-target effects on inflammasome activity in tissues outside the heart, suppressing protective immune responses. Ensuring the drug's selectivity for cardiovascular tissues or immune cells remains problematic, and tissue-targeted delivery systems or prodrugs could be devised to mitigate off-target toxicity and immune complications.

2. Long-Term Safety and Tolerability

Chronic NLRP3 blockade could render host defenses inadequate, thereby paving the way for infection or denying proper tissue repair. Such safety profiles need long-term trials, especially for vulnerable patients like the elderly or those having comorbidities, so as to ascertain if the perks of treatment outweigh the eventual immune risks.[34]

3. Patient Selection and Biomarkers

Identification of a patient population most likely to benefit from NLRP3-targeted therapies remains problematic. There is now an unmet need for reliable biomarkers that would gauge inflammasome activity within cardiovascular disease. Future investigations should try to develop such tools for diagnostic, predictive, and treatment-monitoring purposes in clinical settings.

4. Drug Resistance and Redundancy

The immune system has redundant inflammatory pathways capable of bypassing NLRP3 inhibition, allowing an adverse possibility of drug resistance or decreased efficacy. It can be necessary to target multiple pathways or to combine therapies, with this resulting in treatment regimen complexity along with higher chances of adverse drug reaction and immune modulation.

5. Translating Preclinical Success to Clinical Reality

Though animal models seem promising, realization of these in therapies of human application has not met its promise. The physiologic and immune responses impose limitations on how predictive preclinical studies might be. Some of the future directions include generating humanized models, along with conducting well-designed, multi-center clinical trials that will evaluate these therapeutic outcomes.[35]

CONCLUSION:

The NLRP3 inflammasome has emerged at the very center of cardiovascular disease (CVD) development and progression, acting as a molecular bridge between metabolic stress, immune activation, and vascular dysfunction. Activation by several danger signals, such as ROS, cholesterol crystals, and ATP, leads to chronic inflammation in illnesses like atherosclerosis, myocardial infarction, and heart failure. Therapeutic targeting of NLRP3 or downstream mediators has yielded excellent results in the preclinical and at least peripherally clinical stages, thus opening up a new possible treatment option for CVDs. However, besides therapeutic shortcomings like specificity and safety issues, not many clinical trials have been conducted, thus presenting a gap in knowledge. The heterogeneity of patients and the complicated inflammatory signaling make treatment even more difficult to formulate. Through all these challenges, an ever-deepening understanding of NLRP3 regulation and modulation is the beacon on which we may base hope for future more targeted and efficacious therapies. In its fullest implication, the inflammasome could become the new face for cardiovascular therapeutics and help lessen the global burden from heart diseases.

REFERENCES:

1. Di Cesare M, Perel P, Taylor S, Kabudula C, Bixby H, Gaziano TA, McGhie DV, Mwangi J, Pervan B, Narula J, Pineiro D, Pinto FJ. The Heart of the World. Glob Heart. 2024 Jan 25;19(1):11.
2. Petrie JR, Guzik TJ, Touyz RM. Diabetes, Hypertension, and Cardiovascular Disease: Clinical Insights and Vascular Mechanisms. Can J Cardiol. 2018 May;34(5):575-584
3. Yao, J., Sterling, K., Wang, Z. *et al.* The role of inflammasomes in human diseases and their potential as therapeutic targets. *Sig Transduct Target Ther* **9**, 10 (2024).
4. Chen, Y., Ye, X., Escames, G. *et al.* The NLRP3 inflammasome: contributions to inflammation-related diseases. *Cell Mol Biol Lett* **28**, 51 (2023).
5. Dai Y, Zhou J, Shi C. Inflammasome: structure, biological functions, and therapeutic targets. MedComm (2020). 2023 Oct 9;4(5):e391
6. Chen R, Zou J, Chen J, Zhong X, Kang R, Tang D. Pattern recognition receptors: function, regulation and therapeutic potential. Signal Transduct Target Ther. 2025 Jul 11;10(1):216.
7. Vajjhala PR, Mirams RE, Hill JM. Multiple binding sites on the pyrin domain of ASC protein allow self-association and interaction with NLRP3 protein. J Biol Chem. 2012 Dec 7;287(50):41732-43.
8. Stein R, Kapplusch F, Heymann MC, Russ S, Staroske W, Hedrich CM, Rösen-Wolff A, Hofmann SR. Enzymatically Inactive Procaspase 1 stabilizes the ASC Pyroptosome and Supports Pyroptosome Spreading during Cell Division. J Biol Chem. 2016 Aug 26;291(35):18419-29
9. Zheng D, Liwinski T, Elinav E. Inflammasome activation and regulation: toward a better understanding of complex mechanisms. Cell Discov. 2020 Jun 9;6:36.
10. Kelley N, Jeltema D, Duan Y, He Y. The NLRP3 Inflammasome: An Overview of Mechanisms of Activation and Regulation. Int J Mol Sci. 2019 Jul 6;20(13):3328.
11. Pyrillou K, Burzynski LC, Clarke MCH. Alternative Pathways of IL-1 Activation, and Its Role in Health and Disease. Front Immunol. 2020 Dec 18;11:613170.
12. Khare S, Luc N, Dorfleutner A, Stehlik C. Inflammasomes and their activation. Crit Rev Immunol. 2010;30(5):463-87.
13. Tong Y, Wang Z, Cai L, Lin L, Liu J, Cheng J. NLRP3 Inflammasome and Its Central Role in the Cardiovascular Diseases. Oxid Med Cell Longev. 2020 Apr 14;2020:4293206
14. Swanson KV, Deng M, Ting JP. The NLRP3 inflammasome: molecular activation and regulation to therapeutics. Nat Rev Immunol. 2019 Aug;19(8):477-489

15. Sutterwala FS, Haasken S, Cassel SL. Mechanism of NLRP3 inflammasome activation. Ann N Y Acad Sci. 2014 Jun;1319(1):82-95
16. Latz E, Xiao TS, Stutz A. Activation and regulation of the inflammasomes. Nat Rev Immunol. 2013 Jun;13(6):397-411
17. Raneros AB, Bernet CR, Flórez AB, Suarez-Alvarez B. An Epigenetic Insight into NLRP3 Inflammasome Activation in Inflammation-Related Processes. Biomedicines. 2021 Nov 4;9(11):1614
18. Zheng Y, Xu L, Dong N, Li F. NLRP3 inflammasome: The rising star in cardiovascular diseases. Front Cardiovasc Med. 2022 Sep 20;9:927061
19. Huang Y, Xu W, Zhou R. NLRP3 inflammasome activation and cell death. Cell Mol Immunol. 2021 Sep;18(9):2114-2127
20. Liang JJ, Fraser IDC, Bryant CE. Lipid regulation of NLRP3 inflammasome activity through organelle stress. Trends Immunol. 2021 Sep;42(9):807-823
21. Ji N, Qi Z, Wang Y, Yang X, Yan Z, Li M, Ge Q, Zhang J. Pyroptosis: A New Regulating Mechanism in Cardiovascular Disease. J Inflamm Res. 2021 Jun 22;14:2647-2666.
22. Karasawa T, Takahashi M. Role of NLRP3 Inflammasomes in Atherosclerosis. J Atheroscler Thromb. 2017 May 1;24(5):443-45144
23. Shen S, Wang Z, Sun H, Ma L. Role of NLRP3 Inflammasome in Myocardial Ischemia-Reperfusion Injury and Ventricular Remodeling. Med Sci Monit. 2022 Jan 19;28:e934255
24. Butts B, Gary RA, Dunbar SB, Butler J. The Importance of NLRP3 Inflammasome in Heart Failure. J Card Fail. 2015 Jul;21(7):586-93
25. González-Moro A, Valencia I, Shamoon L, Sánchez-Ferrer CF, Peiró C, de la Cuesta F. NLRP3 Inflammasome in Vascular Disease: A Recurrent Villain to Combat Pharmacologically. Antioxidants (Basel). 2022 Jan 29;11(2):269.
26. Xing Y, Yan L, Li X, Xu Z, Wu X, Gao H, Chen Y, Ma X, Liu J, Zhang J. The relationship between atrial fibrillation and NLRP3 inflammasome: a gut microbiota perspective. Front Immunol. 2023 Nov 21;14:1273524.
27. Chiarini A, Gui L, Viviani C, Armato U, Dal Prà I. NLRP3 Inflammasome's Activation in Acute and Chronic Brain Diseases-An Update on Pathogenetic Mechanisms and Therapeutic Perspectives with Respect to Other Inflammasomes. Biomedicines. 2023 Mar 23;11(4):999.
28. Ding K, Song C, Hu H, Yin K, Huang H, Tang H. The Role of NLRP3 Inflammasome in Diabetic Cardiomyopathy and Its Therapeutic Implications. Oxid Med Cell Longev. 2022 Sep 6;2022:3790721.
29. Das B, Sarkar C, Rawat VS, Kalita D, Deka S, Agnihotri A. Promise of the NLRP3 Inflammasome Inhibitors in In Vivo Disease Models. Molecules. 2021 Aug 18;26(16):4996.
30. Abbate A, Toldo S, Marchetti C, Kron J, Van Tassell BW, Dinarello CA. Interleukin-1 and the Inflammasome as Therapeutic Targets in Cardiovascular Disease. Circ Res. 2020 Apr 24;126(9):1260-1280.
31. Toldo S, Mezzaroma E, Buckley LF, Potere N, Di Nisio M, Biondi-Zoccai G, Van Tassell BW, Abbate A. Targeting the NLRP3 inflammasome in cardiovascular diseases. Pharmacol Ther. 2022 Aug;236:108053
32. Zhao S, Chen F, Yin Q, Wang D, Han W, Zhang Y. Reactive Oxygen Species Interact With NLRP3 Inflammasomes and Are Involved in the Inflammation of Sepsis: From Mechanism to Treatment of Progression. Front Physiol. 2020 Nov 25;11:571810.
33. Watts JK, Corey DR. Silencing disease genes in the laboratory and the clinic. J Pathol. 2012 Jan;226(2):365-79.
34. Singh DD. NLRP3 inflammasome: structure, mechanism, drug-induced organ toxicity, therapeutic strategies, and future perspectives. RSC Med Chem. 2025 May 13.
35. Mo B, Ding Y, Ji Q. NLRP3 inflammasome in cardiovascular diseases: an update. Front Immunol. 2025 Feb 26;16:1550226.